JP7397797B2 - 治療用化合物および組成物 - Google Patents
治療用化合物および組成物 Download PDFInfo
- Publication number
- JP7397797B2 JP7397797B2 JP2020542552A JP2020542552A JP7397797B2 JP 7397797 B2 JP7397797 B2 JP 7397797B2 JP 2020542552 A JP2020542552 A JP 2020542552A JP 2020542552 A JP2020542552 A JP 2020542552A JP 7397797 B2 JP7397797 B2 JP 7397797B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- formula
- subject
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023203652A JP2024023490A (ja) | 2018-02-07 | 2023-12-01 | 治療用化合物および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627435P | 2018-02-07 | 2018-02-07 | |
| US62/627,435 | 2018-02-07 | ||
| PCT/US2019/016503 WO2019156929A1 (en) | 2018-02-07 | 2019-02-04 | Therapeutic compounds and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203652A Division JP2024023490A (ja) | 2018-02-07 | 2023-12-01 | 治療用化合物および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512894A JP2021512894A (ja) | 2021-05-20 |
| JPWO2019156929A5 JPWO2019156929A5 (https=) | 2022-02-14 |
| JP2021512894A5 JP2021512894A5 (https=) | 2022-02-14 |
| JP7397797B2 true JP7397797B2 (ja) | 2023-12-13 |
Family
ID=67548561
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542552A Active JP7397797B2 (ja) | 2018-02-07 | 2019-02-04 | 治療用化合物および組成物 |
| JP2023203652A Pending JP2024023490A (ja) | 2018-02-07 | 2023-12-01 | 治療用化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203652A Pending JP2024023490A (ja) | 2018-02-07 | 2023-12-01 | 治療用化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11691962B2 (https=) |
| EP (1) | EP3749662A4 (https=) |
| JP (2) | JP7397797B2 (https=) |
| KR (1) | KR20200118088A (https=) |
| CN (1) | CN111902404A (https=) |
| AU (1) | AU2019217366B2 (https=) |
| BR (1) | BR112020016123A2 (https=) |
| CA (1) | CA3089970A1 (https=) |
| IL (2) | IL276563B1 (https=) |
| WO (1) | WO2019156929A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| EP3749662A4 (en) | 2018-02-07 | 2021-07-14 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530137A (ja) | 2009-06-16 | 2012-11-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| JP2017507933A (ja) | 2014-02-07 | 2017-03-23 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
| EP1051431A1 (de) | 1998-01-26 | 2000-11-15 | Basf Aktiengesellschaft | Thrombininhibitoren |
| US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
| AU752320B2 (en) | 1998-06-25 | 2002-09-12 | Bristol-Myers Squibb Company | Amidino and guanidino azetidinone tryptase inhibitors |
| AU4654199A (en) | 1998-07-23 | 2000-02-14 | Shionogi & Co., Ltd. | Monocyclic beta-lactam compounds and chymase inhibitors containing the same |
| US20070032466A1 (en) | 2003-08-22 | 2007-02-08 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| CA2648522A1 (en) * | 2005-04-04 | 2006-10-12 | Daiamed, Inc. | Substituted azetidinones |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| ES2674745T3 (es) | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| KR101937514B1 (ko) | 2011-10-14 | 2019-01-10 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물 |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| US20190315711A1 (en) | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3749662A4 (en) | 2018-02-07 | 2021-07-14 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
| KR20210084581A (ko) | 2018-10-30 | 2021-07-07 | 엑시테라 파마슈티컬스 인코퍼레이티드 | 치료 화합물 및 조성물 |
| WO2020092592A1 (en) | 2018-10-30 | 2020-05-07 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3917910A4 (en) | 2019-01-29 | 2022-11-09 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
-
2019
- 2019-02-04 EP EP19751349.2A patent/EP3749662A4/en not_active Withdrawn
- 2019-02-04 BR BR112020016123-3A patent/BR112020016123A2/pt unknown
- 2019-02-04 CA CA3089970A patent/CA3089970A1/en active Pending
- 2019-02-04 AU AU2019217366A patent/AU2019217366B2/en active Active
- 2019-02-04 JP JP2020542552A patent/JP7397797B2/ja active Active
- 2019-02-04 CN CN201980021810.6A patent/CN111902404A/zh active Pending
- 2019-02-04 WO PCT/US2019/016503 patent/WO2019156929A1/en not_active Ceased
- 2019-02-04 KR KR1020207024907A patent/KR20200118088A/ko active Pending
-
2020
- 2020-08-06 US US16/986,658 patent/US11691962B2/en active Active
- 2020-08-06 IL IL276563A patent/IL276563B1/en unknown
-
2023
- 2023-02-17 US US18/170,858 patent/US12152014B2/en active Active
- 2023-12-01 JP JP2023203652A patent/JP2024023490A/ja active Pending
-
2025
- 2025-12-21 IL IL325484A patent/IL325484A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530137A (ja) | 2009-06-16 | 2012-11-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| JP2017507933A (ja) | 2014-02-07 | 2017-03-23 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024023490A (ja) | 2024-02-21 |
| CA3089970A1 (en) | 2019-08-15 |
| CN111902404A (zh) | 2020-11-06 |
| EP3749662A4 (en) | 2021-07-14 |
| KR20200118088A (ko) | 2020-10-14 |
| US12152014B2 (en) | 2024-11-26 |
| AU2019217366B2 (en) | 2024-07-11 |
| US11691962B2 (en) | 2023-07-04 |
| EP3749662A1 (en) | 2020-12-16 |
| AU2019217366A1 (en) | 2020-08-20 |
| BR112020016123A2 (pt) | 2021-02-23 |
| US20240059670A1 (en) | 2024-02-22 |
| IL325484A (en) | 2026-02-01 |
| JP2021512894A (ja) | 2021-05-20 |
| WO2019156929A1 (en) | 2019-08-15 |
| US20210188812A1 (en) | 2021-06-24 |
| RU2020129237A (ru) | 2022-03-09 |
| IL276563A (en) | 2020-09-30 |
| IL276563B1 (en) | 2026-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12084414B2 (en) | Therapeutic compounds and compositions | |
| US20210261524A1 (en) | Therapeutic compounds and compositions | |
| JP2024023490A (ja) | 治療用化合物および組成物 | |
| WO2018118705A1 (en) | Therapeutic compounds and compositions | |
| RU2817800C2 (ru) | Терапевтические соединения и композиции | |
| HK1230083B (zh) | 治療化合物和組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220203 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230901 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231101 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231201 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7397797 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |